SMAD4 loss is associated with response to neoadjuvant chemotherapy plus hydroxychloroquine in patients with pancreatic adenocarcinoma.

Clin Transl Sci · 2021 · PMC8504806 · PMID 34002944

Europe PMC DOI

hedged sentence

0.1800

closest p · 3.6× alpha

0.1800

boldest claim

The sentences

a nonsignificant trendp = 0.18not close (p > 0.1)

There was a nonsignificant trend toward improved median OS in patients treated with HCQ with SMAD4 loss (34.43 months vs. 27.27 months, p = 0.18).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.